A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

NCT06859268 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

643

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity

Interventions

DRUG: Retatrutide
DRUG: Placebo

Sponsor

Eli Lilly and Company